El interés en corto de ENCE Energia y Celulosa da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de ENCE Energia y Celulosa. Los datos de interés en corto se actualizan cada dos semanas.

ENCE Energia y Celulosa (OTC:EEYCF) Bolsa, Informe de interés en corto

ENCE Energia y Celulosa SA produces and sells pulp. The company has two segments namely ENCE Pulp and ENCE Renewables. ENCE Pulp segment includes pulp production and sale activities. ENCE Renewables segment involves Biomass, Biogas, Energy services, and the generation and sale of carbon credits. The vast majority of revenue comes from the ENCE Pulp Segment.

ENCE ENERGIA Y CELSA by Ence Energia Y Celulosa SA

ENCE Energia y Celulosa SA

WestPark Capital analyst Casey Ryan reiterates SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Buy and maintains $31 price target.

News

Price Target

Reiteration

Analyst Ratings

WestPark Capital Reiterates Buy on SentinelOne, Maintains $31 Price Target

MSFT

NVDA

NVIDIA And Microsoft Partner To Bring Neutral Shading Support To Microsoft DirectX, Giving Developers Access To AI Tensor Cores In NVIDIA GeForce RTX GPUs

Canadian Imperial Bank of Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CM#NYSE">CM</a>) has <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44297108/cibc-president-and-ceo-victor-dodig-announces-plan-to-retire-october-31-2025-harry-culham-appointe" rel="noreferrer noopener">announced that its current President </a>and CEO, Victor Dodig, will retire on October 31, 2025.
Harry Culham, who will take over as President and CEO on November 1, 2025, has been appointed Chief Operating Officer effective April 1, 2025.
Dodig will continue to assist in the transition as a special advisor until April 2026, ensuring a smooth leadership handover, the bank reported.
Since taking the helm in 2014, Dodig has steered CIBC through substantial transformation, positioning the bank as a relationship-driven entity recognized for its client focus and strong financial performance.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/03/44277627/ge-aerospace-doubles-down-on-us-manufacturing-with-1b-investment-details" rel="noreferrer noopener">GE Aerospace Doubles Down On US Manufacturing With $1B Investment: Details</a>
Harry Culham is set to lead the bank starting November 1, 2025. Culham first joined CIBC in&nbsp;Vancouver&nbsp;as an intern and participated in one of the bank&#8217;s first ever graduate programs. He rejoined CIBC in 2008, ultimately leadingleading CIBC&#8217;s global Capital Markets business in 2015.
&#8220;Harry is a proven leader who has worked alongside me, our board and the rest of our CIBC team to build the bank we are today,&#8221; said Dodig.
&#8220;His client focus, inclusive leadership and track record of performance and consistency position him perfectly to take the bank forward and build on the momentum we have established. I look forward to working closely with him over the coming months.&#8221;
Culham's efforts have been crucial in transforming CIBC's Capital Markets business, reducing volatility while maintaining high credit quality.
Culham has also led several initiatives at CIBC, including overseeing CIBC Caribbean and CIBC Mellon.
Price Action: CM shares are trading higher by 0.64% at $56.30 in premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44275297/nokia-powers-canal-telecoms-fiber-network-expansion-in-the-caribbean" target="_blank" rel="noreferrer noopener">Nokia Powers Canal+ Telecom&#8217;s Fiber Network Expansion In The Caribbean</a></li>
</ul>
Image via Shutterstock.

Equities

Management

General

Canadian Imperial Bank Picks Harry Culham As Next CEO

WIIM

AEYE

AudioEye shares are trading lower. The company reported Q4 financial results.

Cloudflare shares are trading lower after Needham and Piper Sandler cut their respective price targets on the stock.

Buybacks

CNTM

ConnectM Announces $10M Share Repurchase Program

Bionano Genomics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) today announced a study published in the American Journal of Hematology demonstrating the potential utility of optical genome mapping (OGM) for detecting structural variants associated with chromoanagenesis (CAG) in acute myeloid leukemia (AML). CAG is a catastrophic genomic event that is frequently associated with highly complex karyotypes, extensive clonal heterogeneity, treatment resistance, and poor prognosis compared to subjects with no detectable CAG. Based on the OGM findings, clinical researchers found higher than anticipated rates of CAG in AML (16% of cases overall and approximately two-thirds of cases with high-risk cytogenetic profiles), suggesting that OGM may be more sensitive than traditional cytogenetic methods in identifying aggressive forms of AML.
This study analyzed a prospectively collected cohort of 410 AML cases. It was led by Dr. Guilin Tang, and a team of experts from the MD Anderson Cancer Center, and is the first study known to utilize OGM to study CAG.
Key Findings:
<ul>
<li>CAG was identified in 16% of AML samples and correlated with highly complex karyotypes (92%), monosomal karyotypes (88%), and TP53 mutations (92%)</li>
<li>The median survival for AML subjects with CAG was only 5 months, compared to 14 months in those without CAG</li>
<li>Subjects with CAG had a significantly lower response to combination therapy</li>
<li>OGM provided high resolution and sensitivity in detecting these catastrophic chromosomal events, reinforcing its potential to provide an alternative to refine AML risk stratification and guide treatment planning</li>
</ul>
Erik Holmlin, president and CEO of Bionano commented, "The critical mass of publications underscoring the concordance of OGM with traditional cytogenetics has been established. This impressive study is among a new class of research that is beginning to show the incremental value that OGM can provide above and beyond the standard cytogenetic methods. Using OGM to detect markers like CAG, which is associated with a lower median survival rate and a lower response to therapy, holds the promise that more people with devastating diseases like AML could potentially have access to appropriate therapy sooner."
&nbsp;
The full research publication is available at: <a href="https://www.globenewswire.com/Tracker?data=Zpw22N2e2kFs3YqpbXcVFmbnHHxlC83YhOM3bChZ-qh4aWF8bR1AaMkQkzLKeOmmHCMAEfzN49DHV1RSvEfqdDi4PClz4BdomaB_cXvV2X_AFfUwk4gk3MBASBvOFlHvfJOn8c6Ep7z8c_h9z3WOu6XlPaUVi7pymLtQrRjBx3cAz-zQqAmOStwCD0F1rkLF2RqDndabpvsOt3BrBDkFTnTXoBe2sDGR9_Nwn48cl2lguC7K_-N6eiWoWG-8nEClQXn-FvwEia_-2TNlbjMAlh7pw9gcp315I8zoRiR0y-zc3Iqtrg4GgHV4CQJ8l8mqxMybKPWkYIfVEl6Q5uhUsPv9BJPoq91VvCWIYt_BmVcQm_O2rlo-TCJzjol8CmtynP0-Edb13GV8rt6caA53MPwNUyBgTcSR8HjQ9FrbyZZYlCR34RmWd2XliBV8aml1se0_qkF374fbJhgh77tI6g==">https://onlinelibrary.wiley.com/doi/10.1002/ajh.27575</a>

Biotech

BNGO

Bionano Genomics Announces Study In American Journal Of Hematology On Optical Genome Mapping Detecting 16% Chromoanagenesis In AML Cases, Potentially More Sensitive Than Traditional Methods

DWTX

Dogwood Therapeutics shares are trading lower after the company priced a $4.8 million registered direct offering at $8.26 per share.

CMTL

Comtech Telecommunications shares are trading lower after the company reported a Q2 EPS miss.

WLGS

Wang & Lee Group shares are trading higher after the company announced it acquired SolarHK for HK$15,000,000.

According to the Bureau of Labor Statistics, the headline Consumer Price Index (CPI) dropped from 3.0% in January to 2.8% in February, below economist expectations of 2.9%. With inflation cooling, the possibility of <a href="https://www.benzinga.com/topic/interest-rates">interest rate cuts</a> also come into the picture. 
In this backdrop, certain sectors stand to benefit more than others, such as consumer discretionary, technology and real estate. ETFs with exposure to these sectors also stand to benefit from a cooling inflation (and subsequently rate cuts). Below are some <a href="https://www.benzinga.com/etfs">ETFs to consider</a> in this scenario.
Also Read: <a href="https://www.benzinga.com/25/03/44280431/cpi-reactions">Inflation Moves In The &#8216;Right Direction&#8217; But Forecast Is Hazy, Economist Says</a>
1. Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)
When inflation eases, consumers gain more purchasing power, often leading to higher spending on non-essential goods like apparel, automobiles and entertainment. This benefits the consumer discretionary sector, and consequently XLY.
<ul>
<li>AUM: $20.28 billion</li>
<li>Expense ratio: 0.08%</li>
<li>Index tracked: Consumer Discretionary Select Sector Index</li>
<li>Top holdings: Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>)</li>
</ul>
2. Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)
Being majorly capital intensive, lower inflation and interest rates benefit tech stocks. When borrowing costs fall, tech firms can invest more in innovation and expansion, providing a fillip to profits and stock performance. XLK offers wide exposure to the technology sector, making it a parallel beneficiary.
<ul>
<li>AUM: $64.84 billion</li>
<li>Expense ratio: 0.08%</li>
<li>Index tracked: Technology Select Sector Index</li>
<li>Top holdings: Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
</ul>
3. iShares U.S. Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYR#NYSE">IYR</a>)
The real estate sector often thrives in a low-interest-rate environment. Lower mortgage rates can boost housing demand, while real estate investment trusts (REITs), which typically carry high debt levels, can enjoy cheaper finance operations. IYR provides exposure to U.S. real estate companies and REITs.
<ul>
<li>AUM: $3.57 billion</li>
<li>Expense ratio: 0.39%</li>
<li>Index tracked: Dow Jones U.S. Real Estate Capped Index</li>
<li>Top holdings: Prologis Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>), American Tower Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>), Equinix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>)</li>
</ul>
Economic Backdrop
Inflation cooled in February, a breather investors who had a lot to worry about in the past few weeks. According to the Bureau of Labor Statistics, the <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44285648/wall-street-rebounds-as-cooling-inflation-draws-tech-dip-buyers-whats-driving-markets-wednesday">headline Consumer Price Index (CPI) dropped</a> from 3.0% in January to 2.8% in February, below economist expectations of 2.9%. This marked the first decline after four months of increasing price pressures. Core inflation, which excludes food and energy prices, also moderated, coming in at 3.1% year-over-year, down from 3.3% in January.
These developments reinforce the Federal Reserve's <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44274165/inflation-cools-more-than-expected-in-february-strengthens-the-case-for-fed-rate-cuts">likelihood of cutting interest rates</a> in 2025. Now, economic growth is projected to slow in the first quarter and investment banks have revised GDP forecasts downward, with the Atlanta Fed's GDPNow model predicting a potential 2.4% contraction. This strengthens expectations for rate cuts, as evident from CME FedWatch Tool survey which shows traders assigning nearly an 80% probability of a reduction by June.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/03/44290482/steel-aluminum-import-tariff-threat-4-etfs-gaining-losing-in-the-market-shake-up">Steel &amp; Aluminum Import Tariff Threat: 4 ETFs Gaining &amp; Losing In The Market Shake-Up</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

AAPL

AMZN

BKNG

EQIX

iShares Trust Dow Jones US Real Estate Fund Index

Select Sector SPDR-Consumer Discretionary

Smart ETF Picks For A Cooling Inflation Era

<a href="https://www.wsj.com/finance/currencies/trump-family-has-held-deal-talks-with-binance-following-crypto-exchanges-guilty-plea-05b029fa?mod=latest_headlines" title="https://www.wsj.com/finance/currencies/trump-family-has-held-deal-talks-with-binance-following-crypto-exchanges-guilty-plea-05b029fa?mod=latest_headlines">https://www.wsj.com/finance/currencies/trump-family-has-held-deal-talks-with-binance-following-crypto-exchanges-guilty-plea-05b029fa?mod=latest_headlines</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Economics

Markets

$BTC

'Trump Family Has Held Deal Talks With Binance Following Crypto Exchange's Guilty Plea; Trump-Backed World Liberty Financial Could Be Part Of Binance Deal, Sources Say' - WSJ

SOFI

SoFi Finalizes Up To $5B Loan Platform Business Agreement For Personal Loans With Funds Managed By Blue Owl Capital Funds

Analysts' ratings for Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.71, along with a high estimate of $73.00 and a low estimate of $52.00. A decline of 6.66% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741870918_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Exact Sciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$52.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Exact Sciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Exact Sciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>About Exact Sciences</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Understanding the Numbers: Exact Sciences's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Exact Sciences displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 10.29%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -121.19%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Exact Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -30.81%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Exact Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -13.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.15.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXAS

Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts

During the last three months, 5 analysts shared their evaluations of IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.2, along with a high estimate of $23.00 and a low estimate of $12.00. Surpassing the previous average price target of $17.20, the current average has increased by 11.63%.
<img src="https://www.benzinga.com/files/images/story/2025/1741870905_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive IREN. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mike Colonnese</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Lucas Pipes</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IREN. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of IREN compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into IREN's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IREN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on IREN analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know IREN Better</h2>
IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.
<h3>A Deep Dive into IREN's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: IREN's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 176.1%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: IREN's net margin excels beyond industry benchmarks, reaching 16.06%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): IREN's ROE stands out, surpassing industry averages. With an impressive ROE of 1.56%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): IREN's ROA excels beyond industry benchmarks, reaching 1.21%. This signifies efficient management of assets and strong financial health.
Debt Management: IREN's debt-to-equity ratio is below the industry average at 0.25, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IREN

Breaking Down IREN: 5 Analysts Share Their Views

In the latest quarter, 17 analysts provided ratings for Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Darden Restaurants, revealing an average target of $200.12, a high estimate of $230.00, and a low estimate of $164.00. Surpassing the previous average price target of $187.65, the current average has increased by 6.65%.
<img src="https://www.benzinga.com/files/images/story/2025/1741870894_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Darden Restaurants. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Brian Vaccaro</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Brian Bittner</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$218.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brian Harbour</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$209.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Sara Senatore</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$211.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Strelzik</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Brian Bittner</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Chris O'Cull</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$206.00</td>
<td>$192.00</td>
</tr>
<tr>
<td>Eric Gonzalez</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$194.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$164.00</td>
<td>$164.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Darden Restaurants. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Darden Restaurants compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Darden Restaurants's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Darden Restaurants's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DRI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Darden Restaurants analyst ratings.</a>
<h2>Unveiling the Story Behind Darden Restaurants</h2>
Darden Restaurants is the largest restaurant operator in the US full-service space, with consolidated revenue of $11.4 billion in fiscal 2024 resulting in 3%-4% full-service market share (per NRA data and our calculations). The company maintains a portfolio of 11 restaurant brands: Olive Garden, LongHorn Steakhouse, Cheddar's Scratch Kitchen, Ruth's Chris, Yard House, The Capital Grille, Seasons 52, Eddie V's, Bahama Breeze, The Capital Burger, and most recently, Chuy's. Darden generates revenue almost exclusively from company-owned restaurants, though a small network of franchised restaurants and consumer-packaged goods sales through the traditional grocery channel contribute modestly. As of the end of its fiscal 2024, the company operated 2,031 restaurants in the US.
<h3>Darden Restaurants: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Darden Restaurants's revenue growth over a period of 3 months has been noteworthy. As of 30 November, 2024, the company achieved a revenue growth rate of approximately 5.97%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Darden Restaurants's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.44%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Darden Restaurants's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 10.21%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.8%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 3.06, Darden Restaurants adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Darden Restaurants's Future

DLTH

Duluth shares are trading lower after the company reported worse-than-expected Q4 financial results.

Offerings

Dogwood Therapeutics Prices $4.8M Registered Direct Offering O 578,9950 Shares At $8.26/Share

In the preceding three months, 4 analysts have released ratings for James River Gr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for James River Gr Hldgs, revealing an average target of $6.06, a high estimate of $8.00, and a low estimate of $5.00. This current average has decreased by 21.2% from the previous average price target of $7.69. 
<img src="https://www.benzinga.com/files/images/story/2025/1741870860_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive James River Gr Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Casey Alexander</td>
<td>Compass Point</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.25</td>
<td>$7.75</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to James River Gr Hldgs. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of James River Gr Hldgs compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of James River Gr Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of James River Gr Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/JRVR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on James River Gr Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into James River Gr Hldgs's Background</h2>
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.
<h3>A Deep Dive into James River Gr Hldgs's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining James River Gr Hldgs's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -41.9% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -74.22%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): James River Gr Hldgs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -18.97%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): James River Gr Hldgs's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.89%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: James River Gr Hldgs's debt-to-equity ratio is below the industry average at 0.66, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JRVR

Assessing James River Gr Hldgs: Insights From 4 Financial Analysts

4 analysts have expressed a variety of opinions on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $5.88, a high estimate of $6.50, and a low estimate of $4.00. This current average has decreased by 9.54% from the previous average price target of $6.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1741870850_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Nektar Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$4.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nektar Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Nektar Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Nektar Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Nektar Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NKTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nektar Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Nektar Therapeutics's Background</h2>
Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).
<h3>Nektar Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Negative Revenue Trend: Examining Nektar Therapeutics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -0.08% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Nektar Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -153.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -57.64%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Nektar Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.38%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Nektar Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 2.21. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

ENCE Energia y Celulosa

Interés en corto

ENCE Energia y Celulosa (OTC:EEYCF) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL